Leukemia Clinical Trials
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Leukemia
| Protocol | COG AALL2121 |
|---|---|
| Cancer Type: | leukemia |
| Fast Facts |
COG-AALL2121: A Phase 2 study of SNDX-5613 in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia
Age: Patients must be 1 month to < 6 years old at the time of study enrollment and must have had initial diagnosis of leukemia at < 2 years old.
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | COG AALL1621 |
|---|---|
| Cancer Type: | Relapsed Refractory CD22 B-ALL |
| Fast Facts |
A Phase II Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Patients must be ≥1 Year and < 22 Years of Age at the Time of Enrollment.
| Protocol | COG APAL2020SC |
|---|---|
| Cancer Type: | Relapsed Leukemia |
| Fast Facts |
COG APAL2020SC
Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias
Patients must be less than 22 years of age at the time of study enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.
